id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
33,,,,,,,,,,,,,,,2024-05-02T16:24:47+06:00,BSH - H12207269190,,Trastuzumab + Letrozole,2024-01-16,,"Neo-adjuvant chemotherapy with AC schedule from 17.08.22 to Cycle 4 with AC till
20.10.22 > Started chemotherapy with TPH. Cycle 8 completed on 17.01.23 > Now on Maintenance
Trastuzumab + Femara (Since May 23), M17 due on 16.01.2024
Received Cycle - 1 Inj Zoledronic Acid on 30 July 2023 6 monthly> Then Zoledronic Acid is on hold due
to reaction",,,2024-01-17,,,,,Breast,30,Upper middle class,BSBSC-240000030,HAFAZA KHATUN,1723079659,1970-10-10,Female,,,,,Prof Dr Qamruzzaman Chowdhury,BSH,2.0,Continuous Maintenance,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.3- Lower-inner quadrant of breast,Breast,,,,Stable,Alive,,,,,,,,,,,,,,,,,,,,,,
